Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents, or it may just cause minor leakage. Symptoms include stress incontinence, rashes, and other skin disorders. Risk factors include age, gender, overweight, smoking, and other kidney diseases. Treatment includes anticholinergics and topical estrogen.
The Urinary Incontinence drugs in development market research report provide comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.
Key Targets in the Urinary Incontinence Pipeline Products Market
The key targets in the Urinary Incontinence pipeline products market are Cholinergic Receptor Muscarinic, Synaptosomal Associated Protein 25, 5-Hydroxytryptamine Receptor 2C, 5-Hydroxytryptamine Receptor 3, G Protein Coupled Receptor, Muscarinic Acetylcholine Receptor M1, Muscarinic Acetylcholine Receptor M2, Muscarinic Acetylcholine Receptor M3, and Sodium Dependent Noradrenaline Transporter.
Urinary Incontinence Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Urinary Incontinence Pipeline Products Market
The key mechanisms of action in the Urinary Incontinence pipeline products market are Cholinergic Receptor Muscarinic Antagonist, Synaptosomal Associated Protein 25 Inhibitor, 5-Hydroxytryptamine Receptor 2C Agonist, 5-Hydroxytryptamine Receptor 3 Antagonist, G Protein Coupled Receptor Modulator, Muscarinic Acetylcholine Receptor M1 Antagonist, Muscarinic Acetylcholine Receptor M2 Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, and Sodium Dependent Noradrenaline Transporter Inhibitor.
Urinary Incontinence Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Urinary Incontinence Pipeline Products Market
The key routes of administration in the Urinary Incontinence pipeline products market are intramuscular, parenteral, oral, intradermal, intravesical, subcutaneous, inhalational, intraarticular, intracavernous, intraprostatic, and transdermal.
Urinary Incontinence Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Urinary Incontinence Pipeline Products Market
The key molecule types in the Urinary Incontinence pipeline products market are small molecule, cell therapy, biologic, protein, gene therapy, and oligonucleotide.
Urinary Incontinence Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Urinary Incontinence Pipeline Products Market
Some of the major companies in the Urinary Incontinence pipeline products market are Cook MyoSite Inc, Innovacell Biotechnologie AG, AbbVie Inc, Crystec Ltd, Exopharm Ltd, Ixaltis, Johnson & Johnson, MUVON Therapeutics AG, Ningbo Xijian Pharmaceutical Technology Co Ltd, and Orgenesis Inc.
Urinary Incontinence Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Cholinergic Receptor Muscarinic, Synaptosomal Associated Protein 25, 5-Hydroxytryptamine Receptor 2C, 5-Hydroxytryptamine Receptor 3, G Protein Coupled Receptor, Muscarinic Acetylcholine Receptor M1, Muscarinic Acetylcholine Receptor M2, Muscarinic Acetylcholine Receptor M3, and Sodium Dependent Noradrenaline Transporter |
Key mechanism of action | Cholinergic Receptor Muscarinic Antagonist, Synaptosomal Associated Protein 25 Inhibitor, 5-Hydroxytryptamine Receptor 2C Agonist, 5-Hydroxytryptamine Receptor 3 Antagonist, G Protein Coupled Receptor Modulator, Muscarinic Acetylcholine Receptor M1 Antagonist, Muscarinic Acetylcholine Receptor M2 Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, and Sodium Dependent Noradrenaline Transporter Inhibitor |
Key routes of administration | Intramuscular, Parenteral, Oral, Intradermal, Intravesical, Subcutaneous, Inhalational, Intraarticular, Intracavernous, Intraprostatic, and Transdermal |
Key molecule type | Small Molecule, Cell Therapy, Biologic, Protein, Gene Therapy, and Oligonucleotide |
Major companies | Cook MyoSite Inc, Innovacell Biotechnologie AG, AbbVie Inc, Crystec Ltd, Exopharm Ltd, Ixaltis, Johnson & Johnson, MUVON Therapeutics AG, Ningbo Xijian Pharmaceutical Technology Co Ltd, and Orgenesis Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Cook MyoSite Inc
Crystec Ltd
Exopharm Ltd
Innovacell Biotechnologie AG
Ixaltis
Johnson & Johnson
MUVON Therapeutics AG
Ningbo Xijian Pharmaceutical Technology Co Ltd
Orgenesis Inc
Outpost Medicine Ltd
Pfizer Inc
Profem GmbH
Revance Therapeutics Inc
RION Health Inc
Saniona AB
Sinsin Pharmaceutical Co Ltd
Taiho Pharmaceutical Co Ltd
Urovant Sciences Inc
Versameb AG
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Urinary Incontinence pipeline roducts market?
The key targets in the Urinary Incontinence pipeline products market are Cholinergic Receptor Muscarinic, Synaptosomal Associated Protein 25, 5-Hydroxytryptamine Receptor 2C, 5-Hydroxytryptamine Receptor 3, G Protein Coupled Receptor, Muscarinic Acetylcholine Receptor M1, Muscarinic Acetylcholine Receptor M2, Muscarinic Acetylcholine Receptor M3, and Sodium Dependent Noradrenaline Transporter.
-
What are the key mechanisms of action in the Urinary Incontinence pipeline products market?
The key mechanisms of action in the Urinary Incontinence pipeline products market are Cholinergic Receptor Muscarinic Antagonist, Synaptosomal Associated Protein 25 Inhibitor, 5-Hydroxytryptamine Receptor 2C Agonist, 5-Hydroxytryptamine Receptor 3 Antagonist, G Protein Coupled Receptor Modulator, Muscarinic Acetylcholine Receptor M1 Antagonist, Muscarinic Acetylcholine Receptor M2 Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, and Sodium Dependent Noradrenaline Transporter Inhibitor.
-
What are the key routes of administration in the Urinary Incontinence pipeline products market?
The key routes of administration in the Urinary Incontinence pipeline products market are intramuscular, parenteral, oral, intradermal, intravesical, subcutaneous, inhalational, intraarticular, intracavernous, intraprostatic, and transdermal.
-
What are the key molecule types in the Urinary Incontinence pipeline products market?
The key molecule types in the Urinary Incontinence pipeline products market are small molecule, cell therapy, biologic, protein, gene therapy, and oligonucleotide.
-
Which are the major companies in the Urinary Incontinence pipeline products market?
Some of the major companies in the Urinary Incontinence pipeline products market are Cook MyoSite Inc, Innovacell Biotechnologie AG, AbbVie Inc, Crystec Ltd, Exopharm Ltd, Ixaltis, Johnson & Johnson, MUVON Therapeutics AG, Ningbo Xijian Pharmaceutical Technology Co Ltd, and Orgenesis Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.